Novel erythropoiesis stimulating protein -: NESP -: Darbepoetin alfa -: ARANESP® -: Hematopoietic -: Antianemic -: Oncolytic

被引：0
|
作者：
不详
机构：
来源：
DRUGS OF THE FUTURE | 2001年 / 26卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：304 / 305
页数：2
相关论文
共 50 条
  • [31] A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy
    J Glaspy
    J Singh Jadeja
    G Justice
    J Kessler
    D Richards
    L Schwartzberg
    J Rigas
    D Kuter
    D Harmon
    D Prow
    G Demetri
    D Gordon
    J Arseneau
    A Saven
    H Hynes
    R Boccia
    J O'Byrne
    A B Colowick
    British Journal of Cancer, 2001, 84 : 17 - 23
  • [32] A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy
    Glaspy, J
    Jadeja, JS
    Justice, G
    Kessler, J
    Richards, D
    Schwartzberg, L
    Rigas, J
    Kuter, D
    Harmon, D
    Prow, D
    Demetri, G
    Gordon, D
    Arseneau, J
    Saven, A
    Hynes, H
    Boccia, R
    O'Byrne, J
    Colowick, AB
    BRITISH JOURNAL OF CANCER, 2001, 84 (Suppl 1) : 17 - 23
  • [33] Hematologic outcomes and erythropoiesis-stimulating therapy costs in epoetin alfa (EPO)- and darbepoetin alfa (DARB)-treated cancer patients: Results of the dosing and outcomes study of erythropoiesis-stimulating therapies (DOSE registry).
    Chen, Er
    Peake, Cyrus
    Buscaino, Erminia
    Forlenza, Jamie
    Bookhart, Brahim
    McKenzie, Scott
    BLOOD, 2006, 108 (11) : 953A - 953A
  • [34] The clinical potential of novel erythropoiesis stimulating protein
    Sunder-Plassmann, G
    Hörl, WH
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2001, 1 (04) : 733 - 739
  • [35] Novel erythropoiesis stimulating protein (NESP) administered once every other week corrects anemia in patients with chronic renal insufficiency (CRI)
    Suranyi, M
    Jackson, L
    Lubina, J
    McDermott-Vitak, A
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 37 (04) : A31 - A31
  • [36] A comparative budget impact (BI) analysis of Aranesp® (darbepoetin alfa) 500 μG Q3W versus other erythropoiesis stimulating proteins (ESP) in chemotherapy-induced anemia (CIA) in Spain
    Alcantara, Perez F.
    Badia, X.
    Arocho, R.
    VALUE IN HEALTH, 2006, 9 (06) : A276 - A277
  • [37] An overview of the development and clinical efficacy of novel erythropoiesis stimulating protein (NESP), and practical guidelines for its use in treating renal anaemia - Foreword
    Carrera, F
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 : 1 - 1
  • [38] Randomised, active-controlled phase I/II dose escalation study of novel erythropoiesis stimulating protein (NESP) in patients with solid tumours (presented by the NESP Oncology Study Group).
    Glaspy, J
    Obyrne, J
    Armstrong, S
    Colowick, A
    ANNALS OF ONCOLOGY, 2000, 11 : 146 - 146
  • [39] Physicochemical and biological evaluation of JR-131 as a biosimilar to a long-acting erythropoiesis-stimulating agent darbepoetin alfa
    Tani, Junya
    Ito, Yae
    Tatemichi, Satoshi
    Yamakami, Makoto
    Fukui, Tsuyoshi
    Hatano, Yukichi
    Kakimoto, Shinji
    Kotani, Ayaka
    Sugimura, Atsushi
    Mihara, Kazutoshi
    Yamamoto, Ryuji
    Tanaka, Noboru
    Minami, Kohtaro
    Takahashi, Kenichi
    Hirato, Tohru
    PLOS ONE, 2020, 15 (04):
  • [40] Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naive to erythropoiesis-stimulating agents
    Silver, M. R.
    Geronemus, R.
    Krause, M.
    Chen, C. Y.
    Kewalramani, R.
    Stehman-Breen, C.
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (01) : 123 - 131
12345